GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (LTS:0NZT) » Definitions » Marketable Securities

UCB (LTS:0NZT) Marketable Securities : €195 Mil (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is UCB Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. UCB's Marketable Securities for the quarter that ended in Dec. 2023 was €195 Mil.

UCB's annual Marketable Securities increased from Dec. 2021 (€212 Mil) to Dec. 2022 (€243 Mil) but then declined from Dec. 2022 (€243 Mil) to Dec. 2023 (€195 Mil).

UCB Marketable Securities Historical Data

The historical data trend for UCB's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Marketable Securities Chart

UCB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 139.00 186.00 212.00 243.00 195.00

UCB Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 212.00 475.00 243.00 293.00 195.00

UCB Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

UCB  (LTS:0NZT) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

UCB Marketable Securities Related Terms

Thank you for viewing the detailed overview of UCB's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

UCB (LTS:0NZT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (LTS:0NZT) » Definitions » Marketable Securities
Comparable Companies
XBRU:ARGX XBRU:TUB XBRU:HYL XBRU:ONWD XBRU:ALIMG XBRU:CYAD XBRU:BIOS XBRU:OXUR OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 BNTX OCSE:GMAB ALNY BGNE BMRN
Traded in Other Exchanges
UCBJY:USA UCBJF:USA UCBb:UK UNC:Germany UCB:Belgium UCB:Austria
Address
Allee de la Recherche, 60, Brussels, BEL, B-1070
Website
https://www.ucb.com
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB (LTS:0NZT) Headlines

No Headlines